Class summary at a glance.

Every drug in the 5-alpha Reductase Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 4tracked in Part D
CY24 Part D spend: $199.5Mcombined across class
Total Rx claims: 12.6M4.0M unique beneficiaries
Generic mfrs (active): 22across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Finasteride

Brand: PROPECIA · 11.2M Part D claims (CY24) · 3.5M beneficiaries · First FDA approval: 2006-12-15

9 generic mfrs 0 plans require PA Discontinued

Low NADAC$0.041

→

Avg plan cost$0.438

Part D spend $144.5M 11× spread, current vs floor

Class share

72%

of class CY24 spend

View profile →

Dutasteride

Brand: AVODART · 1.5M Part D claims (CY24) · 481K beneficiaries · First FDA approval: 2015-11-02

10 generic mfrs 0 plans require PA

Low NADAC$0.172

→

Avg plan cost$0.172

Part D spend $55.0M 1× spread, current vs floor

Class share

28%

of class CY24 spend

View profile →

Dutasteride and Tamsulosin

Brand: Jalyn · — Part D claims (CY24) · First FDA approval: 2015-11-18

3 generic mfrs 0 plans require PA

Low NADAC$2.02

→

Avg plan cost$2.02

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Dutasteride and Tamsulosin Hydrochloride Capsules

Brand: Dutasteride and Tamsulosin Hydrochloride · — Part D claims (CY24) · First FDA approval: 2023-11-15

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.